Lebrikizumab,Abbexa,abx831187
Lebrikizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL13, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
Host
Human
Reactivity
Human
Application
ELISA, WB
Conjugate
Unconjugated
Platform ID
BAB732554397
Abbexa
Contact
Tel: +44 (0) 1223 755950
Fax: +44 (0) 1223 755951
Email:
Product Specifications
Specifications
NameLebrikizumab
Cat. No.abx831187
HostHuman
IsotypeIgG4 Kappa
ReactivityHuman
ConjugationUnconjugated
ApplicationELISA, WB
Working DilutionsOptimal dilutions/concentrations should be determined by the end user.
ClonalityMonoclonal
Concentration1.28 mg/ml
TargetIL13
PurityPurified from cell culture supernatants by Protein A/G chromatography.
Appearance/FormLiquid
Formulation0.01 M PBS. pH 7.4.
StorageAliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Regulatory StatusResearch Use Only
Category Paths
- Products>Primary Antibodies>Biosimilar Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.